Here are the S-3 shelf registrations from NextCure, Inc. (NXTC) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An S-3 covers the shelf registration that lets an established company sell over time, so if you follow NXTC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NXTC filings page.
NextCure, Inc. is registering 2,523,477 shares of common stock for resale by selling stockholders under a shelf prospectus. The shares consist of 708,428 outstanding shares and 1,815,049 shares issuable upon exercise of pre-funded warrants issued in a November 12, 2025 private placement.
Investors in that private placement bought common stock at $8.52 per share and pre-funded warrants at $8.519 per warrant, raising approximately $21.5 million in gross proceeds for NextCure before fees. The warrants are exercisable at $0.001 per share and do not expire.
NextCure will not receive proceeds from any resale of the 2,523,477 shares, but would receive about $1,815 if all pre-funded warrants are exercised, which it expects to use for working capital and general corporate purposes. Shares outstanding were 5,203,299 as of November 25, 2025, assuming full warrant exercise. The company’s common stock trades on Nasdaq under the symbol “NXTC.”